🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Stoked to receive the 2023 Clinical Research Award at Memorial Sloan Kettering Cancer Center Dept Surgery Graduation. Thx to incredible mentors Behfar Ehdaie Karim Touijer James Eastham @morr316 and co-fellows Proud to represent UrologyMSK Society of Urologic Oncology USANZ Austin Health GU Cast | Urology podcast! Fulbright Australia

Sad to say goodbye to NYC 🗽and my UrologyMSK family Ben Beech Carissa Chu Song Jiang Sari Khaleel Wesley Yip ari hakimi Thanks for making the American experience unforgettable. Excited to see what the future brings for this group of crazy smart uro-oncologists ❤️

🥇Very exciting day for our Urology team led James Eastham 🥇!!! health.usnews.com/best-hospitals…

Outcomes of Grade Group 2 and 3 PCa on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance buff.ly/3PSQuie marlon perera Ghalib Jibara Daniel Sjoberg Sigrid Carlsson Vincent Laudone Karim Touijer Samson W. Fine, MD Andrew Vickers Behfar Ehdaie

We are very pleased to announce this year's Virtual Open House for interested SUO Fellowship Applicants. Please join us on November 15th at 7pm EST. RSVP to receive a Zoom link to join us-- forms.gle/gRzjKmzvDzUtRM…

#KUA2023 opening session on case with high PSA and one pelvic node - work of ⁦Michael Hofman⁩ ⁦marlon perera⁩ on role of PSMA recognised ⁦USANZ⁩ ⁦USANZ Training⁩

Comparison of 18F-based #PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of #prostatecancer — a systematic review and meta-analysis: nature.com/articles/s4139… marlon perera

FAPI PET - Highlighting the promising data on one of the latest PET candidates in RCC rdcu.be/dujX8 Michael Hofman Shankar Siva Cristian Udovicich GU Cast | Urology podcast! #ejnmmi

From GU onc at #EAU24 to GU energy gels at Schneider Electric Marathon de Paris. Paris you’ve been a blast 🇫🇷🥐

August's #CaseOfTheMonth is from the Peter Mac Cancer Centre: an operative approach to large renal #angiomyolipoma associated with lymphangioleiomyomatosis Jonathan O'Brien Marc Diocera Declan Murphy Nathan Lawrentschuk Pocharapong Jenjitranant marlon perera David Gyorki bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

Dr marlon perera on Sub-stratification of Intermediate Risk #ProstateCancer | “w the same amount of Pattern 4, why does the amount of Pattern 3, dictate mx for GG 2-3 dse?” | #apcc24 Peter Mac Cancer Centre Memorial Sloan Kettering Cancer Center 🟩🟩🟩🟩⬜️= GG1 🟥🟥🟩🟩🟩= GG2 🟥🟥🟩🟩⬜️= GG3

Words of Wisdom Wednesday: Re: First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma by Alice Thomson et al Read the full article here: buff.ly/4eoYGjN #UroSoMe

Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors buff.ly/3UON4PS

Should prostate RT be an option for all men with de novo mCSPC (high and low volume), despite systemic intensification? Check out our Dr. Andrew Loblaw The Lancet editorial on PEACE-1 RT. ↗️ rPFS and castrate resistance-free survival in low volume ↘️ serious GU AEs regardless of

Peter Mac has been named Australia's leading #cancer research institute in The Australian newspaper's Research 2025 Magazine, and four of our researchers were named as leader in their field. Read more: petermac.org/about-us/news-…

Impact of intraprostatic PSMA SUVmax following prostatectomy: a systematic review and meta-analysis First publication of 2025 - congrats David Chen marlon perera BJU International doi.org/10.1111/bju.16… "Preoperative intraprostatic PSMA SUVmax increases monotonically with higher ISUP

Is there a role for PSMA PET/CT in oligometatastic RCC? Check out our JNM PEDESTAL study on PSMA-guided metastasis-directed therapy from Peter Mac Cancer Centre Shankar Siva Michael Hofman 🧍33 pts & 60 metastases 🛜 93% radiotherapy 📖Median follow-up> 4y ✅Local control: 94%

Now published in Urologic Oncology by UrologyMSK Jonathan Coleman, Paul Russo, ari hakimi et al.: Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors doi.org/10.1016/j.urol…

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence. 🚨Meta-analysis of 43 studies (n=8,119) ⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats Declan Murphy marlon perera + team European Association of Urology (EAU)! ➡️link shorturl.at/unfn5

The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment sciencedirect.com/science/articl… systematic review and